Department of Pharmacy, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia.
Department of Clinical Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
BMC Nephrol. 2024 Oct 7;25(1):332. doi: 10.1186/s12882-024-03773-x.
Patients with chronic kidney disease frequently face various nutritional and metabolic problems that necessitate the use of multiple medications. This multiple drug use can lead to several drug-related problems including adverse drug events, hospital admissions, poor medication adherence, harmful drug interactions, inadequate therapeutic outcomes, and death. Despite these challenges, there is a notable lack of studies on the extent of multiple drug use and its determinants among patients with chronic kidney disease in Ethiopia. This study aims to assess the magnitude of multiple drug use and identify the determinants of vulnerability among patients with chronic kidney disease in Ethiopia.
A hospital-based cross-sectional study was conducted among patients with chronic kidney disease. Eligible participants were selected using a simple random sampling technique. Frequency and percentage calculations were performed for categorical variables, while means and standard deviations were used for continuous variables. The chi-square test and t-test were used to compare the proportions and means, respectively. Binary logistic regression was used to identify the determinants of multiple drug use, with statistical significance determined by a p-value of less than 0.05 and a 95% confidence interval. Guidelines and previous literature were utilized to assess the magnitude of multiple drug use.
A total of 230 patients were enrolled, with more than half being male. The overall magnitude of multiple drug use was 83.0%. Diuretics being the most frequently prescribed medication class followed by angiotensin converting enzyme inhibitors. Patients aged 65 years and above (AOR = 4.91 (95% CI 1.60-15.03)), CKD stage five (AOR) = 5.48 (95% CI 1.99-15.09)), and the presence of comorbid conditions (AOR) = 3.53 (95% CI 1.55-8.06)) were significantly associated with multiple drug use.
Chronic kidney disease patients exhibited a high rate of multiple drug use. The presence of comorbid conditions, disease progression and older age are significant determinates of this vulnerability. Health care providers should pay particular attention to these factors to manage and mitigate the risks associated with multiple drug use.
慢性肾脏病患者经常面临各种营养和代谢问题,需要使用多种药物。这种多药使用会导致多种药物相关问题,包括药物不良事件、住院、药物依从性差、有害药物相互作用、治疗效果不佳和死亡。尽管存在这些挑战,但在埃塞俄比亚,关于慢性肾脏病患者多药使用的程度及其决定因素的研究却很少。本研究旨在评估埃塞俄比亚慢性肾脏病患者多药使用的程度,并确定其易感性的决定因素。
采用基于医院的横断面研究,对慢性肾脏病患者进行研究。采用简单随机抽样技术选择合格的参与者。对分类变量进行频率和百分比计算,对连续变量进行均值和标准差计算。采用卡方检验和 t 检验分别比较比例和均值。采用二项逻辑回归识别多药使用的决定因素,以 p 值<0.05 和 95%置信区间为统计学意义标准。指南和以前的文献用于评估多药使用的程度。
共纳入 230 名患者,其中一半以上为男性。多药使用的总体程度为 83.0%。利尿剂是最常开的药物类别,其次是血管紧张素转换酶抑制剂。65 岁及以上的患者(AOR=4.91(95%CI 1.60-15.03))、CKD 五期(AOR=5.48(95%CI 1.99-15.09))和合并症(AOR=3.53(95%CI 1.55-8.06))的患者与多药使用显著相关。
慢性肾脏病患者多药使用率较高。合并症、疾病进展和年龄较大是易感性的重要决定因素。医疗保健提供者应特别注意这些因素,以管理和减轻多药使用相关的风险。